Objective: We aimed to investigate the echocardiographic characteristics of workers with resting major electrocardiography (ECG) anomalies and risk factors of sudden cardiac death in the large Turkish workers population in different heavy industry sectors. Methods: Between April 2016 and January 2020, 8668 consecutive ECGs were obtained and interpreted during health examinations of working in İstanbul, Turkey. ECGs were classified as major, minor anomaly, and normal according to the Minnesota code criteria. The workers with major anomaly on ECGs, recurrent syncope attacks, and family history (FH) of sudden or inexplicably death under the age of 50 and with a positive FH of cardiomyopathy were also referred to further transthoracic echocardiographic (TTE) examination. Results: The mean age of the workers was 30.47 ± 9.4 years, most of them were male (97.1%) and under the age of 30 (54.2%). Major ECG changes were detected in 4.6%, and minor anomalies were 28.3%. A total of 663 workers were referred to our cardiology clinic for advanced TTE examination, but only 578 (87.17% of the selected) attended the appointment. Four hundred and sixty‐seven (80.7%) echocardiography examinations were within normal limits. Echocardiographic imaging revealed abnormal findings in 98 cases (25.7%) in the ECG abnormalities group, three (4.4%) in the syncope group, and 10 (7.6%) in the positive FH group (p < .001). Conclusions: This work demonstrated the ECG findings and echocardiographic features of a large sample of Turkish workers from high‐risk employment sectors. This is the first study conducted in Turkey on this subject.
Background: Drug-eluting stents (DES) have higher marked efficacy and lower revascularization requirements compared to bare metal stents (BMS).We aimed to determine the mid-term outcomes of patients implanted with a first-generation DES "paclitaxel-eluting stents" (PES). Methods: Patients with at least 1 PES implanted in our cardiology clinic were received in the nonrandomized group. Inclusion criteria were all patients undergoing percutaneous coronary intervention and PES implantation. The mean follow-up time was 35.14 + 13.4 months. Results: A total of 302 patients (401 lesions and 337 PES) were enrolled in the study. The mean age was 61.86 + 10.27 years. Major adverse cardiac and cerebrovascular events (MACE) occurred at 17.9%, and the stent thrombosis rate was 4%. Independent predictors of stent thrombosis were serum creatinine levels [OR 1.59; 95% CI, 1.03-2.46, p=0.03] and mean platelet volume [OR 1.59; 95% CI, 1.03-2.46, p= 0.03]. Also, poor functional capacity [OR 2.46: 95% CI, 1.42-4.26, p<0.001] and positive ischemia test [OR 3.43: 95% CI, (1.73-6.82), p<0.001] were predictors of MACE's. Conclusions: We have demonstrated that PES is safe and effective in the mid-term for use in coronary artery disease.
Background: Enlargement of the pulmonary artery (PA) could be helpful in risk stratification by the chest CT on the admission of COVID-19 patients. Methods: This study aimed to associate PA diameter and overall mortality in COVID-19 pneumonia. We designed a retrospective study between January 2021 and May 2021 in tertiary-level hospitals in Gebze, Turkey. Subjects were evaluated in two groups according to their survivor status (survivors and non-survivors). Then biochemical, demographic, and clinical values were compared via the groups to define the predictive value of PA diameter on chest CT images. Results: In the enrolled 594 COVID-19 in-hospital patients (median age was 45 (34-58) years, 263patients (44.3%) were female. 44 patients (7.4%) died during hospitalization. Multivariate Cox-proportion regression model yielded main PA ≥ 29 mm on admission showed that as independent predictors of death (long rank <0.001, median survival time 28 days). Cumulative survival rates were MPAD ≥ 29 mm 45% and < 29 mm 90% yielded (p < 0.001) Conclusions: PA dilatation is strongly linked with in-hospital mortality in hospitalized patients with COVID-19 infection. Thus increased PA diameter on chest CT at admission may guide rapid and early diagnosis of high-risk patients.
Introduction: Inflammation and malnutrition may trigger heart failure development and progression (HF). However, the relationship of the modified Glasgow prognostic score (mGPS), which is derived from C-reactive protein and albumin with mildly reduced ejection fraction HF (HFmrEF), is not well-known. We aimed to determine whether the modified Glasgow prognostic score (mGPS) is helpful for the prediction of all-cause mortality in patients with HFmrEF. Patients and Methods: Patients with HFmrEF admitted to our outpatient clinic between January 2016 and January 2020 were enrolled. All-cause mortality was defined as the primary endpoint. The mGPS was calculated and, its association with overall survival was determined. Results: Data were analyzed for 259 patients. The mGPS≤ 1 in 172 (66%), and 2 in 87 (34%) patients, respectively. Higher mGPS was related to worse results of routine biomarkers associated with prognosis, especially NT-proBNP [777 (112-4564) pg/mL vs. 350 (65-3521) pg/mL, respectively, p< 0.0001)]. In multivariable Cox model, NT-proBNP [1.83 (1.32-2.55), p< 0.0001], mGPS 2 vs. ≤1 [2.43 (1.2-4.93), p= 0.013], and coronary artery disease (CAD) [3.15 (1.46-6.82), p= 0.003] were found to be independently associated with all-cause mortality. Conclusion: The immune-nutritional score mGPS predicts mortality during long-term follow-up of patients with HFmrEF. The mGPS might be used for risk status assessment of HFmrEF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.